BT
ALNY icon

Banque Transatlantique’s Alnylam Pharmaceuticals ALNY Stock Holding History

Banque Transatlantique’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Buy
692
+150
+28% +$45.2K ﹤0.01% 287
2026
Q1 		$179K Buy
+542
New +$184K ﹤0.01% 258

Other funds holding ALNY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Banque Transatlantique's ALNY Position: Q2 2026 in Review

Banque Transatlantique increased its Alnylam Pharmaceuticals (ALNY) stake by 28% in Q2 2026, buying an estimated $45.2K and bringing the position to 692 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #287.

Banque Transatlantique first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. 365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Banque Transatlantique held 692 shares of Alnylam Pharmaceuticals worth $208K as of Q2 2026.
  • Banque Transatlantique bought 150 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $45.2K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Banque Transatlantique's portfolio in Q2 2026, its #287 holding.
  • Banque Transatlantique first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Banque Transatlantique's 13F filing for Q2 2026, filed 30 Jul 2026.